A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs DCR PH1 (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; First in man
- Sponsors Dicerna Pharmaceuticals
- 10 Aug 2017 Status changed from active, no longer recruiting to discontinued according to a Dicerna Pharmaceuticals media release.
- 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 13 May 2016 According to a Dicerna Pharmaceuticals media release, the first patient has been dosed in this trial.